A
Apellis Pharmaceuticals, Inc. (APLS)
NMS – Real Time Price. Currency in USD
16.97
-0.67 (-3.80%)
At close: Mar 27, 2026, 4:00 PM EDT
16.99
+0.02 (0.12%)
After-hours: Mar 27, 2026, 7:54 PM EDT

NMS – Real Time Price. Currency in USD
16.97
-0.67 (-3.80%)
At close: Mar 27, 2026, 4:00 PM EDT
16.99
+0.02 (0.12%)
After-hours: Mar 27, 2026, 7:54 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.14 | 6.05 | 10 | |
| Quick ratio | 2.70 | 5.63 | 10 | |
| Debt to Equity | 1.28 | 0.30 | 5.0 | |
| Debt to Assets | 0.44 | 1.04 | 5.0 | |
| Interest coverage | -4.71 | -16.91 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 75M | 397M | 781M | 1B | 1B |
| Gross Profit | 68M | 336M | 664M | 902M | 900M |
| Operating Income | -595M | -517M | -165M | 55M | 55M |
| Net Income | -652M | -529M | -198M | 22M | 22M |
| EBITDA | -593M | -515M | -163M | 57M | 57M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 21.85 | 52.36 | 10 |
| Next quarter | 16.36 | 3.54 | 6.5 |
| Current year | -14.17 | -661.39 | 1.0 |
| Next year | 18.52 | 82.62 | 9.5 |
| Weighted average score | 6.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -56.4 | -127.32 | -128.13 | -113.18 | 1.0 |
| Y/Y | -5.93 | -62.15 | -62.06 | -173.85 | 1.0 |
| 3y average | 183.77 | 64.27 | 68.06 | 73.54 | 10 |
| 5y average | 98.24 | 17.81 | 28.41 | -2.14 | 7.5 |
| Weighted average score | 4.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $467.8M barely cover the upcoming debt maturities $474.4M
Total current assets $1.0B exceed Total current liabilities $323.6M, highlighting excellent liquidity
Debt-to-equity ratio (1.3) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-4.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$14.3M limits the company's ability to reinvest or pay down debt